DTIL — Precision Biosciences Income Statement
0.000.00%
Last trade - 00:00
- $67.39m
- -$47.92m
- $48.73m
- 26
- 35
- 79
- 44
2019 December 31st | 2020 December 31st | C2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 22.2 | 24.3 | 116 | 25.1 | 48.7 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 109 | 134 | 149 | 98.3 | 92.5 |
Operating Profit | -87.2 | -110 | -33.4 | -73.2 | -43.7 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -92.9 | -109 | -30.6 | -72.9 | -42.5 |
Net Income After Taxes | -92.9 | -109 | -30.6 | -72.9 | -42.5 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -92.9 | -109 | -30.6 | -112 | -61.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -92.9 | -109 | -30.6 | -112 | -61.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -66.4 | -62.9 | -18.7 | -21.2 | -11 |